Long term outcomes of phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early failure oral cancer

Author:

Babanrao Dhumal SachinORCID,Patil Vijay,Parekh DeevyashaliORCID,Noronha Vanita,Menon Nandini,Peelay Zoya,Prakash Nawale Kavita,Prabhash KumarORCID

Publisher

Elsevier BV

Reference25 articles.

1. Metronomic chemotherapy in advanced oral cancers;Patil;J Cancer Res Therapeut,2012

2. Head and neck cancer;Argiris;Lancet,2008

3. Laskar SG, Chaukar D, Deshpande M, et al. Phase III randomized trial of surgery followed by conventional radiotherapy (5 fr/Wk)(Arm A) vs concurrent chemoradiotherapy (Arm B) vs accelerated radiotherapy (6fr/Wk)(Arm C) in locally advanced, stage III and IV, resectable, squamous cell carcinoma of oral cavity-oral cavity adjuvant therapy (OCAT): final results (NCT00193843).

4. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression;Ferris;Oral Oncol,2018

5. CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer;Gillison;Oncol,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3